185 related articles for article (PubMed ID: 32551397)
1. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial.
Frye BC; Rump IC; Uhlmann A; Schubach F; Ihorst G; Grimbacher B; Zissel G; Quernheim JM
Contemp Clin Trials Commun; 2020 Sep; 19():100575. PubMed ID: 32551397
[TBL] [Abstract][Full Text] [Related]
2. The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial.
Krausz M; Uhlmann A; Rump IC; Ihorst G; Goldacker S; Sogkas G; Posadas-Cantera S; Schmidt R; Feißt M; Alsina L; Dybedal I; Recher M; Warnatz K; Grimbacher B
Contemp Clin Trials Commun; 2022 Dec; 30():101008. PubMed ID: 36262801
[TBL] [Abstract][Full Text] [Related]
3. FeV1 and BMI influence King's Sarcoidosis Questionnaire score in sarcoidosis patients.
Frye BC; Potasso L; Farin-Glattacker E; Birring S; Müller-Quernheim J; Schupp JC
BMC Pulm Med; 2021 Dec; 21(1):395. PubMed ID: 34861850
[TBL] [Abstract][Full Text] [Related]
4. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
5. Novel Approach in Cardiac Sarcoidosis: A Case Report Highlighting Abatacept as a Promising Treatment Option.
Venkataraj M; Pierotti T; Sondhi M; Balmuri S; Hayat S
Cureus; 2023 Sep; 15(9):e45805. PubMed ID: 37876386
[TBL] [Abstract][Full Text] [Related]
6. Translation and psychometric properties of the King's Sarcoidosis Questionnaire (KSQ) in German language.
Farin E; Heyduck K; Frye BC; Birring SS; Müller-Quernheim J; Schupp JC
Health Qual Life Outcomes; 2019 Apr; 17(1):62. PubMed ID: 30975148
[TBL] [Abstract][Full Text] [Related]
7. Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study.
Kahlmann V; Janssen Bonás M; Moor CC; van Moorsel CHM; Kool M; Kraaijvanger R; Grutters JC; Overgaauw M; Veltkamp M; Wijsenbeek MS;
BMC Pulm Med; 2020 Oct; 20(1):271. PubMed ID: 33076885
[TBL] [Abstract][Full Text] [Related]
8. Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.
Picchianti Diamanti A; Rosado MM; Scarsella M; Germano V; Giorda E; Cascioli S; Laganà B; D'Amelio R; Carsetti R
Clin Exp Immunol; 2014 Sep; 177(3):630-40. PubMed ID: 24773026
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study.
Baughman RP; Judson MA; Beaumont JL; Maier LA; Sweiss NJ; Culver DA; Chen ES; Singh N; Lower EE; Reeves R; Hamzeh N; Grutters JC; Valeyre D; Birring SS
Ann Am Thorac Soc; 2021 Mar; 18(3):477-485. PubMed ID: 32970455
[No Abstract] [Full Text] [Related]
10. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
Massarotti EM
Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
[TBL] [Abstract][Full Text] [Related]
11. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML; Haavardsholm EA; Rudin A; Nordström D; Nurmohamed M; Gudbjornsson B; Lampa J; Hørslev-Petersen K; Uhlig T; Grondal G; Østergaard M; Heiberg MS; Twisk J; Lend K; Krabbe S; Hyldstrup LH; Lindqvist J; Hultgård Ekwall AK; Grøn KL; Kapetanovic M; Faustini F; Tuompo R; Lorenzen T; Cagnotto G; Baecklund E; Hendricks O; Vedder D; Sokka-Isler T; Husmark T; Ljoså MA; Brodin E; Ellingsen T; Söderbergh A; Rizk M; Olsson ÅR; Larsson P; Uhrenholt L; Just SA; Stevens DJ; Laurberg TB; Bakland G; Olsen IC; van Vollenhoven R;
BMJ; 2020 Dec; 371():m4328. PubMed ID: 33268527
[TBL] [Abstract][Full Text] [Related]
12. Exposure-response analyses of efzofitimod in patients with pulmonary sarcoidosis.
Walker G; Adams R; Guy L; Chandrasekaran A; Kinnersley N; Ramesh P; Zhang L; Brown F; Niranjan V
Front Pharmacol; 2023; 14():1258236. PubMed ID: 37854715
[No Abstract] [Full Text] [Related]
13. Abatacept Use Is Associated with Steroid Dose Reduction and Improvement in Fatigue and CD4-Dysregulation in CVID Patients with Interstitial Lung Disease.
von Spee-Mayer C; Echternach C; Agarwal P; Gutenberger S; Soetedjo V; Goldacker S; Warnatz K
J Allergy Clin Immunol Pract; 2021 Feb; 9(2):760-770.e10. PubMed ID: 33223097
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
15. Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study.
Balandraud N; Texier G; Massy E; Muis-Pistor O; Martin M; Auger I; Guzian MC; Guis S; Pham T; Roudier J
PLoS One; 2017; 12(2):e0171623. PubMed ID: 28199343
[TBL] [Abstract][Full Text] [Related]
16. King's Sarcoidosis Questionnaire (KSQ) - Validation study in Serbian speaking population of sarcoidosis patients.
Stjepanovic M; Mihailovic-Vucinic V; Gvozdenovic BS; Milin-Lazovic J; Belic S; Djurdjevic N; Maric N; Golubovic A
PLoS One; 2023; 18(9):e0273126. PubMed ID: 37669301
[TBL] [Abstract][Full Text] [Related]
17. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.
Schiff M; Pritchard C; Huffstutter JE; Rodriguez-Valverde V; Durez P; Zhou X; Li T; Bahrt K; Kelly S; Le Bars M; Genovese MC
Ann Rheum Dis; 2009 Nov; 68(11):1708-14. PubMed ID: 19074911
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
[TBL] [Abstract][Full Text] [Related]
19. ProKaSaRe Study Protocol: A Prospective Multicenter Study of Pulmonary Rehabilitation of Patients With Sarcoidosis.
Lingner H; Großhennig A; Flunkert K; Buhr-Schinner H; Heitmann R; Tönnesmann U; van der Meyden J; Schultz K
JMIR Res Protoc; 2015 Dec; 4(4):e134. PubMed ID: 26679102
[TBL] [Abstract][Full Text] [Related]
20. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
